Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial
PT Heath, EP Galiza, DN Baxter… - Clinical Infectious …, 2023 - academic.oup.com
Background The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7%
efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-…
efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-…
Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1. 7 variant
PT Heath, EP Galiza, DN Baxter, M Boffito, D Browne… - MedRxiv, 2021 - medrxiv.org
Background Covid-19 vaccines are urgently needed, especially against emerging variants.
NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-…
NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-…
[HTML][HTML] The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insight
O Bird, EP Galiza, DN Baxter, M Boffito… - Epidemiology and …, 2024 - ncbi.nlm.nih.gov
To investigate the symptoms of SARS-CoV-2 infection, their dynamics and their discriminatory
power for the disease using longitudinally, prospectively collected information reported at …
power for the disease using longitudinally, prospectively collected information reported at …
The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insight
O Bird, EP Galiza, DN Baxter, M Boffito… - Epidemiology & …, 2024 - cambridge.org
To investigate the symptoms of SARS-CoV-2 infection, their dynamics and their discriminatory
power for the disease using longitudinally, prospectively collected information reported at …
power for the disease using longitudinally, prospectively collected information reported at …
Nutrition adequacy therapeutic enhancement in the critically ill: a randomized double‐blind, placebo‐controlled trial of the motilin receptor agonist camicinal …
…, F Lamontagne, GE Dukes, D Neil… - Journal of parenteral …, 2018 - Wiley Online Library
Background Camicinal is a novel, nonmacrolide, motilin receptor agonist that accelerates
gastric emptying in critically ill patients with established feed intolerance. The primary question …
gastric emptying in critically ill patients with established feed intolerance. The primary question …
[HTML][HTML] Classification and personalized prognosis in myeloproliferative neoplasms
J Grinfeld, J Nangalia, EJ Baxter… - … England Journal of …, 2018 - Mass Medical Soc
Background Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia,
and myelofibrosis, are chronic hematologic cancers with varied progression rates. …
and myelofibrosis, are chronic hematologic cancers with varied progression rates. …
Why Scrum works in new product development: the role of social capital in managing complexity
Major changes are currently underway across new product development (NPD) practice, and
a number of new NPD management methods and processes are emerging. Managers are …
a number of new NPD management methods and processes are emerging. Managers are …
Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies
…, P Sköld, PW Andrews, MA Baxter… - Stem cells …, 2015 - academic.oup.com
The field of stem cell therapeutics is moving ever closer to widespread application in the clinic.
However, despite the undoubted potential held by these therapies, the balance between …
However, despite the undoubted potential held by these therapies, the balance between …
How to Enable Ambidexterity in Safety-Critical Software Development: This article reports on a safety-critical development project that achieved ambidexterity and …
Overview: In a competitive environment, continually improving new products and services
requires new knowledge and novel solutions. Managing projects also requires the careful …
requires new knowledge and novel solutions. Managing projects also requires the careful …
[HTML][HTML] Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme
…, CMC Rodrigues, K Davis, A Bartolf, D Baxter… - Clinical Microbiology …, 2022 - Elsevier
Objective Serogroup W and Y invasive meningococcal disease increased globally from
2000 onwards. Responding to a rapid increase in serogroup W clonal complex 11 (W:cc11) …
2000 onwards. Responding to a rapid increase in serogroup W clonal complex 11 (W:cc11) …